Results 1 to 10 of about 54,884 (249)

Regional and intratumoral adoptive T-cell therapy [PDF]

Immuno-Oncology and Technology
Adoptive T-cell therapies (ACTs) including tumor-infiltrating lymphocytes and engineered T cells (transgenic T-cell receptor and chimeric antigen receptor T cells), have made an important impact in the field of cancer treatment over the past years.
I. Olivera, I. Etxeberria, C. Luri-Rey, P. Molero-Glez, I. Melero   +4 more
doaj   +4 more sources

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy [PDF]

Nature Communications
Neoantigen-based adoptive T cell therapies (ACTs) represent a promising avenue in cancer immunotherapy due to their exquisite tumor specificity. The first cell-based immunotherapy for a solid tumor, comprising tumor-infiltrating lymphocytes, recently ...
Divya Lenkala, Jessica Kohler, Brian McCarthy, Michael Nelson, Noor A. M. Bakker, Renate de Boer, Emily K. Jackson, Joong Hyuk F. Sheen, Susan Hannes, Ekaterina Esaulova, Kai Stewart, Claudia Gottstein, John Attanasio, Flavian D. Brown, Sebastian Hymson, Shirisha Meda, Maaike van Zon, Saskia Scheij, Rhianne Voogd, Brenda Raud, Ziyan Xu, Jessica S. W. Borgers, Maartje W. Rohaan, Kristen N. Balogh, Asaf Poran, Michael Rooney, Jesse Z. Dong, John R. Srouji, Vikram R. Juneja, Christina M. Arieta, Cynthia M. Nijenhuis, Bastiaan Nuijen, Mark DeMario, Kelledy Manson, Ton N. M. Schumacher, Richard B. Gaynor, John B. Haanen, Joost H. van den Berg, Marit M. van Buuren   +38 more
doaj   +2 more sources

Optimization of culture media for ex vivo T-cell expansion for adoptive T-cell therapy [PDF]

Advanced Biomedical Research, 2022
Background: Adoptive T-cell therapy is a promising treatment strategy for cancer immunotherapy. The ability of immunotherapy based on the adoptive cell transfer of genetically modified T cells to generate powerful clinical responses has been highlighted ...
Ilnaz Rahimmanesh, Mehrsa Tavangar, Seyedeh Noushin Zahedi, Yadollah Azizi, Hossein Khanahmad Shahreza   +4 more
doaj   +2 more sources

Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors [PDF]

Signal Transduction and Targeted Therapy
The intricate tumor microenvironment presents formidable obstacles to the efficacy of adoptive T cell therapy in the management of solid tumors by limiting the infiltration and inducing exhaustion of the transferred T cells.
Chaojie Zhu, Chao Liu, Qing Wu, Tao Sheng, Ruyi Zhou, En Ren, Ruizhe Zhang, Zhengjie Zhao, Jiaqi Shi, Xinyuan Shen, Zhongquan Sun, Zhengwei Mao, Kaixin He, Lingxiao Zhang, Yuan Ding, Zhen Gu, Weilin Wang, Hongjun Li   +17 more
doaj   +2 more sources

The potential and promise for clinical application of adoptive T cell therapy in cancer [PDF]

Journal of Translational Medicine
Adoptive cell therapy has revolutionized cancer treatment, especially for hematologic malignancies. T cells are the most extensively utilized cells in adoptive cell therapy.
Yinqi Li, Yeteng Zheng, Taiqing Liu, Chuanyun Liao, Guobo Shen, Zhiyao He   +5 more
doaj   +2 more sources

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors [PDF]

Nature Communications, 2023
KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to eliminate tumor cells. In
Dan Lu, Yuan Chen, Min Jiang, Jie Wang, Yiting Li, Keke Ma, Wenqiao Sun, Xing Zheng, Jianxun Qi, Wenjing Jin, Yu Chen, Yan Chai, Catherine W. H. Zhang, Hao Liang, Shuguang Tan, George F. Gao   +15 more
doaj   +2 more sources

Reprogramming the tumor microenvironment to boost adoptive T cell therapy [PDF]

Frontiers in Immunology
Adoptive T cell therapies (ACT) have revolutionized the management of hematologic malignancies; however, their efficacy in solid tumors remains limited.
Maria Fernanda Meza Pacheco, Maria Fernanda Meza Pacheco, Lee-Hwa Tai, Lee-Hwa Tai   +3 more
doaj   +2 more sources

Enhanced tumor response to adoptive T cell therapy with PHD2/3-deficient CD8 T cells [PDF]

Nature Communications
While adoptive cell therapy has shown success in hematological malignancies, its potential against solid tumors is hindered by an immunosuppressive tumor microenvironment (TME).
Tereza Dvorakova, Veronica Finisguerra, Matteo Formenti, Axelle Loriot, Loubna Boudhan, Jingjing Zhu, Benoit J. Van den Eynde   +6 more
doaj   +2 more sources

CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer [PDF]

Molecular Therapy: Nucleic Acids
The CD3/T cell receptor (TCR) complex is responsible for antigen-specific pathogen recognition by T cells, and initiates the signaling cascade necessary for activation of effector functions.
Ashwathi Puravankara Menon, Helena Villanueva, Daniel Meraviglia-Crivelli, Hisse M. van Santen, Joschka Hellmeier, Angelina Zheleva, Francesca Nonateli, Timo Peters, Tassilo L.A. Wachsmann, Mercedes Hernandez-Rueda, Johannes B. Huppa, Gerhard J. Schütz, Eva Sevcsik, Beatriz Moreno, Fernando Pastor   +14 more
doaj   +2 more sources

Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors. [PDF]

Front Immunol
Kadyrzhanova G, Tamai M, Sarkar S, Kalra RS, Ishikawa H.   +4 more
europepmc   +2 more sources